188 related articles for article (PubMed ID: 32713439)
61. Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Ryan DP; Fernandez-del Castillo C; Willett CG; Brugge WR; Sahani D; Brachtel EF
N Engl J Med; 2005 Jun; 352(26):2734-41. PubMed ID: 15987923
[No Abstract] [Full Text] [Related]
62. Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas.
Wolff RA
Curr Drug Targets; 2012 Jun; 13(6):781-8. PubMed ID: 22458524
[TBL] [Abstract][Full Text] [Related]
63. Management of borderline and locally advanced pancreatic cancer: where do we stand?
He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
[TBL] [Abstract][Full Text] [Related]
64. Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
Chen Q; Cui SP; Wang D; Lang R
Asian J Surg; 2023 Apr; 46(4):1824-1825. PubMed ID: 36369134
[No Abstract] [Full Text] [Related]
65. Pancreatic cancer-improved care achievable.
Buanes TA
World J Gastroenterol; 2014 Aug; 20(30):10405-18. PubMed ID: 25132756
[TBL] [Abstract][Full Text] [Related]
66. Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence.
Brown ZJ; Ruff SM; Cloyd JM
Curr Opin Pharmacol; 2022 Dec; 67():102305. PubMed ID: 36223686
[TBL] [Abstract][Full Text] [Related]
67. Validation of group B borderline resectable pancreatic cancer: retrospective analysis.
Oh TG; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Kang CM; Lee WJ; Park JY
Gut Liver; 2014 Sep; 8(5):557-62. PubMed ID: 25228978
[TBL] [Abstract][Full Text] [Related]
68. Surgical exploration with non-resection in the setting of resectable, borderline and locally advanced pancreatic cancer.
Søreide K
Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):205-206. PubMed ID: 35221247
[No Abstract] [Full Text] [Related]
69. Novel Considerations in Surgical Management of Individuals with Pancreatic Adenocarcinoma.
Barnes CA; Tsai S
Hematol Oncol Clin North Am; 2022 Oct; 36(5):979-994. PubMed ID: 36265994
[TBL] [Abstract][Full Text] [Related]
70. Invited commentary for the article "Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy?".
Hewitt DB; Wolfgang CL
Surgery; 2023 May; 173(5):1229-1230. PubMed ID: 36854642
[No Abstract] [Full Text] [Related]
71. Pancreatic cancer: advances in treatment.
Mohammed S; Van Buren G; Fisher WE
World J Gastroenterol; 2014 Jul; 20(28):9354-60. PubMed ID: 25071330
[TBL] [Abstract][Full Text] [Related]
72. Neoadjuvant treatment in localized and resectable cancer of the pancreas: a new therapeutic paradigm.
MartÃ-Cruchaga P; Cienfuegos JA; Rotellar F
Rev Esp Enferm Dig; 2022 Jul; 114(7):371-374. PubMed ID: 35638765
[TBL] [Abstract][Full Text] [Related]
73. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.
Katz MH; Marsh R; Herman JM; Shi Q; Collison E; Venook AP; Kindler HL; Alberts SR; Philip P; Lowy AM; Pisters PW; Posner MC; Berlin JD; Ahmad SA
Ann Surg Oncol; 2013 Aug; 20(8):2787-95. PubMed ID: 23435609
[TBL] [Abstract][Full Text] [Related]
74. Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
Ren L; Mota Reyes C; Friess H; Demir IE
Langenbecks Arch Surg; 2020 Nov; 405(7):879-887. PubMed ID: 32776259
[TBL] [Abstract][Full Text] [Related]
75. [A Case of Pathological Complete Response after Neoadjuvant Therapy for Resectable Pancreatic Cancer].
Shimojima Y; Nomura T; Takano K; Nakayasu Y; Kono T; Kuhara K; Usui T; Asaka S; Yokomizo H; Shimakawa T; Ohigashi S; Shiozawa S
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1662-1664. PubMed ID: 36733168
[TBL] [Abstract][Full Text] [Related]
76. Perioperative and Survival Outcomes Following Neoadjuvant FOLFIRINOX versus Gemcitabine Abraxane in Patients with Pancreatic Adenocarcinoma.
Chapman BC; Gleisner A; Rigg D; Messersmith W; Paniccia A; Meguid C; Gajdos C; McCarter MD; Schulick RD; Edil BH
JOP; 2018 Mar; 19(2):75-85. PubMed ID: 29950957
[TBL] [Abstract][Full Text] [Related]
77. Neoadjuvant modified-FOLFIRINOX followed by surgical resection of both the primary and metastatic tumors of a pancreatic hepatoid carcinoma with synchronous liver metastasis: A case report.
Ma T; Bai X; Li G; Wei S; Liang T
Medicine (Baltimore); 2017 Oct; 96(43):e8413. PubMed ID: 29069039
[TBL] [Abstract][Full Text] [Related]
78. Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer.
Liu M; Wei AC
Hematol Oncol Clin North Am; 2024 Jun; 38(3):629-642. PubMed ID: 38429197
[TBL] [Abstract][Full Text] [Related]
79. Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Underwood PW; Cloyd JM
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38568860
[No Abstract] [Full Text] [Related]
80. [Neoadjuvant treatment concepts for borderline-resectable adenocarcinoma of the pancreas].
Roth S; Schneider M
Chirurgie (Heidelb); 2022 Oct; 93(10):995-996. PubMed ID: 36063204
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
